Core Insights - Agomab Therapeutics has received U.S. Patent No. 12,577,230 for AGMB-447, an investigational inhaled small molecule inhibitor targeting ALK5 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) [1][2] - The patent provides intellectual property protection for AGMB-447 in the U.S. until at least 2041, excluding potential extensions [1] - AGMB-447 is designed to inhibit fibrosis specifically in the lungs while minimizing systemic exposure, aiming to offer a novel therapeutic option for IPF patients [3] Company Overview - Agomab is a clinical-stage biopharmaceutical company focused on developing therapies for fibro-inflammatory diseases with significant unmet medical needs [4] - The company aims to create organ-restricted therapies that enhance efficacy and reduce safety liabilities, with a mission to improve the quality of life for patients suffering from these disorders [4]
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis